Mineralys holder may sell $3.0M in shares

A shareholder of Mineralys Therapeutics filed a Rule 144 notice to potentially sell 104,320 common shares acquired in a 2022 private transaction.

Available on EDGAR 09/22/2026 - 04:10 PM EDT Accepted by SEC EDGAR 09/22/2026 - 04:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) is the issuer of common stock for which Catalys Pacific Fund has filed a notice to sell shares under Rule 144. The notice covers 104,320 shares of common stock, with an indicated aggregate market value of $3,005,302.72 and notes 88,406,885 shares outstanding as of September 22, 2026.

The shares to be sold were acquired on June 1, 2022 in a private acquisition from the issuer or an affiliate for cash. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker for potential sales on NASDAQ.

Key Figures

Shares to be sold: 104,320 shares Aggregate market value: $3,005,302.72 Shares outstanding: 88,406,885 shares +2 more

5 metrics

Shares to be sold 104,320 shares Maximum common shares covered by the Rule 144 notice

Aggregate market value $3,005,302.72 Aggregate market value of 104,320 shares referenced in the notice

Shares outstanding 88,406,885 shares Common shares outstanding as of September 22, 2026

Acquisition date June 1, 2022 Date shares were acquired in a private acquisition from issuer/affiliate for cash

Planned sale date reference September 22, 2026 Date referenced in the securities information and signature sections

Key Terms

Rule 144, Private Acquisition from Issuer/Affiliate, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Private Acquisition from Issuer/Affiliate financial

"Common | 06/01/2022 | Private Acquisition from Issuer/Affiliate | Issuer"

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... | 3005302.72"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Mineralys Therapeutics (MLYS)?

The Form 144 notice states that Catalys Pacific Fund may sell up to 104,320 shares of Mineralys Therapeutics common stock under Rule 144. It is a notice of a potential resale by an existing holder, not an issuance of new shares by Mineralys.

How many Mineralys Therapeutics (MLYS) shares are covered by this Form 144?

The notice covers up to 104,320 shares of Mineralys Therapeutics common stock. These shares are listed with an aggregate market value of $3,005,302.72 in the Form 144 securities information section.

What is the aggregate market value of the Mineralys Therapeutics (MLYS) shares in this Form 144?

The Form 144 lists an aggregate market value of $3,005,302.72 for the 104,320 shares of Mineralys Therapeutics common stock that may be sold by Catalys Pacific Fund through Morgan Stanley Smith Barney LLC.

When and how did the selling holder acquire the Mineralys Therapeutics (MLYS) shares?

The shares were acquired on June 1, 2022 in a Private Acquisition from Issuer/Affiliate for cash. This acquisition date and method are disclosed in the securities-to-be-sold section of the Form 144.

How many Mineralys Therapeutics (MLYS) shares are outstanding according to this Form 144?

The Form 144 notes that there are 88,406,885 shares of Mineralys Therapeutics common stock outstanding as of September 22, 2026; this is a baseline figure, not the amount being offered for sale.

Which broker is named for the potential sale of Mineralys Therapeutics (MLYS) shares?

The notice identifies Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza as the broker for the potential sale of the 104,320 Mineralys Therapeutics common shares, with trading listed on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001746274
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MINERALYS THERAPEUTICS, INC.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	CATALYS PACIFIC FUND LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	104320	3005302.72	88406885	09/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/01/2022	Private Acquisition from Issuer/Affiliate	Issuer			104320	06/01/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Brian Taylor Slingsby
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)